Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.

PR Newswire March 27, 2014

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland

Equities.com March 24, 2014

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report

PR Newswire March 14, 2014

BioDelivery Sciences to Present at the 26th Annual ROTH Conference

PR Newswire March 5, 2014

BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference

PR Newswire February 28, 2014

BioDelivery Sciences Closes $60 Million Registered Direct Offering

PR Newswire February 13, 2014

BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors

PR Newswire February 10, 2014

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference

PR Newswire January 30, 2014

Five Star Equities Issues New Research Reports on ATOS, BDSI, PTCT and TNXP

Accesswire January 28, 2014

Endo and BioDelivery Sciences Announce Positive Top-Line Results from the Phase III Clinical Trial of BEMA Buprenorphine in Opioid Naive Patients with Chronic Pain

PR Newswire January 23, 2014

BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones

PR Newswire January 10, 2014

BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets

PR Newswire December 3, 2013

Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy

PR Newswire December 2, 2013

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials

PR Newswire November 12, 2013

BioDelivery Sciences Appoints Ernest De Paolantonio as Chief Financial Officer

PR Newswire October 21, 2013

BioDelivery Sciences Announces FDA Acceptance of BUNAVAIL NDA for Filing

PR Newswire October 9, 2013

BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference

PR Newswire September 6, 2013

Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program

PR Newswire September 4, 2013

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials

PR Newswire August 9, 2013

BioDelivery Sciences Announces Submission of NDA for BUNAVAIL

PR Newswire August 1, 2013